Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Mark Payne

Showing results (51-60 of 67) with videos related to

Pageof 7
Sort By:
Journal of Computer Assisted Tomography|November 13, 2004
Evaluation of the quantitative capability of a high-resolution positron emission tomography scanner for small animal imagingFrederic H Fahey, H Donald Gage, Nancy Buchheimer, et al.
JCI Insight|July 21, 2017
Nicotinamide mononucleotide requires SIRT3 to improve cardiac function and bioenergetics in a Friedreich's ataxia cardiomyopathy modelAngelical S Martin, Dennis M Abraham, Kathleen A Hershberger, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|December 15, 2012
Common data elements for clinical research in Friedreich's ataxiaDavid R Lynch, Massimo Pandolfo, Jorg B Schulz, et al.
International Journal of Molecular Sciences|August 10, 2024
A Barth Syndrome Patient-Derived <i>D75H</i> Point Mutation in <i>TAFAZZIN</i> Drives Progressive Cardiomyopathy in MicePaige L Snider, Elizabeth A Sierra Potchanant, Zejin Sun, et al.
Journal of the American Heart Association|March 20, 2026
Ex Vivo Effect of Apixaban on Hemostatic Biomarkers in Children With Heart Disease: A SAXOPHONE Trial SubstudyGhada A Aborkhees, Amy J Barr, Kevin Dietrich, et al.
Clinical Pharmacology and Therapeutics|June 24, 2025
Characterization of Apixaban Pharmacokinetics/Pharmacodynamics and Dose Assessment in Pediatric Patients with Congenital or Acquired Heart DiseaseAntoinette Ajavon-Hartmann, Praneeth Jarugula, Hyunmoon Back, et al.
American Heart Journal|June 5, 2017
Results of a phase I/II multi-center investigation of udenafil in adolescents after fontan palliationDavid J Goldberg, Victor Zak, Bryan H Goldstein, et al.
American Heart Journal|June 19, 2018
Design and rationale of the Fontan Udenafil Exercise Longitudinal (FUEL) trialDavid J Goldberg, Victor Zak, Bryan H Goldstein, et al.
Journal of the American Heart Association|March 26, 2025
Methylated Arginine Metabolites as Biomarkers for Clinical Status and Response to Type 5 Phosphodiesterase Inhibition in Patients With Fontan CirculationAri Cedars, Cedric Manlhiot, Bhargava Kumar Chinni, et al.
Journal of the American College of Cardiology|December 6, 2023
Apixaban for Prevention of Thromboembolism in Pediatric Heart DiseaseR Mark Payne, Kristin M Burns, Andrew C Glatz, et al.
Pageof 7

Showing results (51-60 of 67) with videos related to

Sort By:
Pageof 7
Journal of Computer Assisted Tomography|November 13, 2004
Evaluation of the quantitative capability of a high-resolution positron emission tomography scanner for small animal imagingFrederic H Fahey, H Donald Gage, Nancy Buchheimer, et al.
JCI Insight|July 21, 2017
Nicotinamide mononucleotide requires SIRT3 to improve cardiac function and bioenergetics in a Friedreich's ataxia cardiomyopathy modelAngelical S Martin, Dennis M Abraham, Kathleen A Hershberger, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|December 15, 2012
Common data elements for clinical research in Friedreich's ataxiaDavid R Lynch, Massimo Pandolfo, Jorg B Schulz, et al.
International Journal of Molecular Sciences|August 10, 2024
A Barth Syndrome Patient-Derived <i>D75H</i> Point Mutation in <i>TAFAZZIN</i> Drives Progressive Cardiomyopathy in MicePaige L Snider, Elizabeth A Sierra Potchanant, Zejin Sun, et al.
Journal of the American Heart Association|March 20, 2026
Ex Vivo Effect of Apixaban on Hemostatic Biomarkers in Children With Heart Disease: A SAXOPHONE Trial SubstudyGhada A Aborkhees, Amy J Barr, Kevin Dietrich, et al.
Clinical Pharmacology and Therapeutics|June 24, 2025
Characterization of Apixaban Pharmacokinetics/Pharmacodynamics and Dose Assessment in Pediatric Patients with Congenital or Acquired Heart DiseaseAntoinette Ajavon-Hartmann, Praneeth Jarugula, Hyunmoon Back, et al.
American Heart Journal|June 5, 2017
Results of a phase I/II multi-center investigation of udenafil in adolescents after fontan palliationDavid J Goldberg, Victor Zak, Bryan H Goldstein, et al.
American Heart Journal|June 19, 2018
Design and rationale of the Fontan Udenafil Exercise Longitudinal (FUEL) trialDavid J Goldberg, Victor Zak, Bryan H Goldstein, et al.
Journal of the American Heart Association|March 26, 2025
Methylated Arginine Metabolites as Biomarkers for Clinical Status and Response to Type 5 Phosphodiesterase Inhibition in Patients With Fontan CirculationAri Cedars, Cedric Manlhiot, Bhargava Kumar Chinni, et al.
Journal of the American College of Cardiology|December 6, 2023
Apixaban for Prevention of Thromboembolism in Pediatric Heart DiseaseR Mark Payne, Kristin M Burns, Andrew C Glatz, et al.
Pageof 7